The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 05, 2016

Filed:

Apr. 05, 2013
Applicant:

Optiscan Biomedical Corporation, Hayward, CA (US);

Inventor:

Peter Rule, Los Altos Hills, CA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); A61M 31/00 (2006.01); A61M 5/172 (2006.01); A61B 5/155 (2006.01); A61B 5/145 (2006.01); A61B 5/1455 (2006.01); G06F 19/00 (2011.01); A61M 5/168 (2006.01); A61M 5/14 (2006.01); A61M 5/142 (2006.01);
U.S. Cl.
CPC ...
A61M 5/1723 (2013.01); A61B 5/1427 (2013.01); A61B 5/14532 (2013.01); A61B 5/14535 (2013.01); A61B 5/14546 (2013.01); A61B 5/14557 (2013.01); A61B 5/155 (2013.01); A61B 5/412 (2013.01); A61B 5/4839 (2013.01); A61B 5/7475 (2013.01); G06F 19/3468 (2013.01); A61M 5/16827 (2013.01); A61M 2005/1404 (2013.01); A61M 2005/14208 (2013.01); A61M 2005/1726 (2013.01); A61M 2205/12 (2013.01); A61M 2230/201 (2013.01);
Abstract

Disclosed are methods and apparatuses for determining analyte concentration in a sample such as bodily fluid. Systems and methods disclosed herein can also include a treatment dosing system to infuse or inject a treatment dose (e.g. insulin, dextrose, etc.) and provide glycemic control. The dose of the treatment drug may be based on the patient's calculated sensitivity to treatment dosing, for example. The dose of the treatment drug may be based on the concentration of the analyte or the average value for the concentration of the analyte and/or the rate of change of the value of the concentration of the analyte. Delivery of the treatment drug can be cut off if the determined analyte concentration indicates that continued delivery would be harmful to the patient.


Find Patent Forward Citations

Loading…